MCW Cancer Center Launches MyeloMATCH to Advance Precision Medicine for Myeloid Cancers
The MCW Cancer Center’s Clinical Trials Office recently activated the phase 2 MyeloMATCH screening study, that tests patients’ blood and bone marrow for biomarkers to guide treatment decisions and match them to personalized clinical trials.
Pilot Funding Aims to Unlock the Secrets of Endocrine Resistance in Breast Cancer
The Our Patient Project study lays the foundation for more personalized treatment strategies, ensuring patients can receive therapies suited to their cancer’s unique biology.
Protein Levels May Predict Breast Cancer Recurrence
MCW Cancer Center scientists find that patients with elevated levels of a particular protein may experience an early recurrence of certain breast cancers.
Scientists Identify FOXM1 Protein as a Key Driver of Myeloma Metabolism
In a recent study, investigators take a closer look at the metabolic role of genes to determine the genetic and biological pathways associated with high-risk myeloma and relapsed/refractory myeloma. The research opens the door to new therapies and prevention.
Understanding Precision Oncology
By harnessing our knowledge of cutting-edge precision medicine techniques to treat hematological malignancies, MCW Cancer Center scientists have been able to identify new approaches to directly target cancer cells, while sparing healthy tissues and achieving cures with less toxicity.
This approach is already being applied to our other clinical areas of expertise including pancreatic, prostate, brain, and gynecological cancers. These cancers, while universally detrimental, also impact populations in our community very differently and accentuate racial, socioeconomic, and gender disparities.
Our goal is to solve for these disparities and create opportunities for more patients to receive personalized and effective therapeutic treatments for cancer.
The MCW Cancer Center’s investment in precision oncology brings together investigators across the research continuum and with expertise in cancer genomics and epigenomics to focus on translating discoveries to in-house clinical trials, tailored to the unique needs of our patient population.